The Study of Envafolimab Combined With Concurrent Chemoradiotherapy In LS-SCLC

NCT05904015 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

80

Enrollment

OTHER

Sponsor class

Conditions

Lung Neoplasms

Interventions

DRUG: Envafolimab combined with concurrent chemoradiotherapy (Hypofractionated radiotherapy)
DRUG: Envafolimab combined with concurrent chemoradiotherapy (Conventional Radiotherapy)

Sponsor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences